S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Regulus Therapeutics (RGLS) Stock Forecast, Price & News

+0.02 (+9.70%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.44 million shs
Average Volume
4.26 million shs
Market Capitalization
$33.01 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Regulus Therapeutics logo

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$10.01 million
Book Value
$0.34 per share


Net Income
$-27.81 million
Pretax Margin




Free Float
Market Cap
$33.01 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.24 out of 5 stars

Medical Sector

323rd out of 1,416 stocks

Pharmaceutical Preparations Industry

125th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

Is Regulus Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Regulus Therapeutics stock.
View analyst ratings for Regulus Therapeutics
or view top-rated stocks.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Regulus Therapeutics

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). During the same quarter in the previous year, the company posted ($0.08) EPS.
View Regulus Therapeutics' earnings history

What price target have analysts set for RGLS?

2 brokerages have issued twelve-month price objectives for Regulus Therapeutics' stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Regulus Therapeutics' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 784.6% from the stock's current price.
View analysts' price targets for Regulus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Regulus Therapeutics' key executives?
Regulus Therapeutics' management team includes the following people:
What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics CEO Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among Regulus Therapeutics' employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (19.90%), Vanguard Group Inc. (2.52%), Northern Trust Corp (0.12%), Renaissance Technologies LLC (0.09%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends for Regulus Therapeutics

Which major investors are selling Regulus Therapeutics stock?

RGLS stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
View insider buying and selling activity for Regulus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Regulus Therapeutics stock?

RGLS stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Vanguard Group Inc., Renaissance Technologies LLC, and Northern Trust Corp. Company insiders that have bought Regulus Therapeutics stock in the last two years include Denis Drygin, Joseph P Hagan, and Paul Edward Walker.
View insider buying and selling activity for Regulus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.23.

How much money does Regulus Therapeutics make?

Regulus Therapeutics has a market capitalization of $33.01 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-27.81 million in net income (profit) each year or ($0.300010) on an earnings per share basis.

How many employees does Regulus Therapeutics have?

Regulus Therapeutics employs 26 workers across the globe.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is www.regulusrx.com.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at cont[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.